BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park J, Jung KS, Lee HW, Kim BK, Kim SU, Kim DY, Ahn SH, Han KH, Park JY. Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis. Gut Liver. 2017;11:828-834. [PMID: 28651305 DOI: 10.5009/gnl16484] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. [PMID: 29405329 DOI: 10.1002/hep.29800] [Cited by in Crossref: 1129] [Cited by in F6Publishing: 998] [Article Influence: 282.3] [Reference Citation Analysis]
2 Lee HY, Oh H, Park CH, Yeo YH, Nguyen MH, Jun DW. Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis. World J Gastroenterol 2019; 25(23): 2961-2972 [PMID: 31249453 DOI: 10.3748/wjg.v25.i23.2961] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Verna EC. Updated Hepatitis B Guidance: Implications for liver transplant patients. Liver Transpl 2018;24:465-9. [PMID: 29466838 DOI: 10.1002/lt.25037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Vu V, Trinh S, Le A, Johnson T, Hoang J, Jeong D, Henry L, Barnett S, Cheung R, Nguyen MH. Hepatitis B and renal function: A matched study comparing non-hepatitis B, untreated, treated and cirrhotic hepatitis patients. Liver Int 2019;39:655-66. [PMID: 30460749 DOI: 10.1111/liv.14009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lim TS, Lee JS, Kim BK, Lee HW, Jeon MY, Kim SU, Park JY, Kim DY, Han KH, Ahn SH. An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. J Viral Hepat 2020;27:316-22. [PMID: 31639240 DOI: 10.1111/jvh.13222] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Ahn SH, Kim W, Jung YK, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Um SH, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Yim HJ, Lee KS, Lim YS, Lee WS, Park NH, Jin SY, Kim KH, Choi W, Han KH. Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2019; 17: 1850-1859. e4. [PMID: 30448598 DOI: 10.1016/j.cgh.2018.11.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
7 Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13514] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
8 Oh H, Jun DW. Can We Trust Safety of Tenofovir Disoproxil in Patients with Decompensated Cirrhosis? Gut Liver 2017;11:743-4. [PMID: 29081210 DOI: 10.5009/gnl17401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
9 Zheng H, Liu H, Hao A, Zhang M, Wang D. Association between serum Cystatin C and renal injury in patients with chronic hepatitis B. Medicine (Baltimore) 2020;99:e21551. [PMID: 32769895 DOI: 10.1097/MD.0000000000021551] [Reference Citation Analysis]
10 Luo J, You X, Chong Y, Wu Y, Gong J, Jie Y, Li X, Xi S, Zhang Z, Zhang Y, Xie D, Li Z, Li X. Efficacy of long-term treatment with tenofovir in Chinese nucleos(t)ide-naïve chronic hepatitis B patients regardless of baseline viral load. Exp Ther Med 2019;18:260-8. [PMID: 31258661 DOI: 10.3892/etm.2019.7547] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Hsu YC, Wei MT, Nguyen MH. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev Gastroenterol Hepatol 2017;11:999-1008. [PMID: 28965428 DOI: 10.1080/17474124.2017.1386554] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
12 Lee D, Yun BC, Seo KI, Han BH, Lee SU, Park ET, Lee JW, Jeong J. Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate. Medicine (Baltimore) 2019;98:e18351. [PMID: 31852136 DOI: 10.1097/MD.0000000000018351] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Kim SJ, Rhu J, Lee SH, Kim JM, Choi GS, Kim K, Joh JW. Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients. Ann Surg Treat Res 2020;99:180-7. [PMID: 32908850 DOI: 10.4174/astr.2020.99.3.180] [Reference Citation Analysis]
14 Wen Z, Feng Y, Yan X. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol 2021;74:245-6. [PMID: 33008623 DOI: 10.1016/j.jhep.2020.07.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Buti M, Roade L, Riveiro-Barciela M, Esteban R. Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues. Liver Int 2020;40 Suppl 1:15-21. [PMID: 32077604 DOI: 10.1111/liv.14367] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
16 Trinh S, Le AK, Chang ET, Hoang J, Jeong D, Chung M, Lee MH, Wang U, Henry L, Cheung R, Nguyen MH. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir. Clin Gastroenterol Hepatol. 2019;17:948-956.e1. [PMID: 30130625 DOI: 10.1016/j.cgh.2018.08.037] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]